较新的治疗方案有望改善转移性和不可切除黑色素瘤的治疗效果。这项调查的目的是回顾这些治疗皮肤眼睑和眼眶疾病的方法。在 PubMed 数据库中搜索与该主题相关的文章，并对这些手稿的参考书目进行审查，以确保捕获适当的文献。数据被提取和分析。从历史上看，患有眼附属器黑色素瘤的患者表现不佳。采用 BRAF 和丝裂原相关蛋白激酶抑制剂、免疫疗法和新型细胞疗法的方法可改善结果和生存率，尽管这些药物的副作用存在问题。大多数现有策略并未专门探讨眼附件疾病，治疗计划通常改编自普通皮肤肿瘤学文献。由于我们对该疾病细胞生物学的理解不断进步，不可切除和转移性黑色素瘤的治疗已取得了长足的进步过去几年。新的治疗方法可能会继续提高生存率并减少不良事件。

Newer treatment options offer the promise of improved outcomes for metastatic and unresectable melanoma. This investigation was performed to review these modalities for cutaneous eyelid and orbital disease.A search for articles that were related to this subject was performed in the PubMed database, and the bibliographies of these manuscripts were reviewed to ensure capture of the appropriate literature. Data was abstracted and analyzed.Historically, patients who suffer from melanoma of the ocular adnexa have fared poorly. Approaches that employ BRAF and mitogen-associated protein kinase inhibitors, immunotherapy, and novel cellular therapies improve outcomes and survival rates, although the side effect profiles of these agents are problematic. Most of the existing strategies have not explored ocular adnexal disease specifically, and treatment plans are generally adapted from the general cutaneous oncology literature.Thanks to advances in our comprehension of the cellular biology of the disease, the management of unresectable and metastatic melanoma has evolved considerably over the past several years. Newer modalities will likely continue to improve survival and reduce adverse events.